Novavax (NVAX) COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Go back to Novavax (NVAX) COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

June 14, 2021 6:00 AM EDT

93% efficacy against predominantly circulating Variants of Concern and Variants of Interest 91% efficacy in high-risk populations 100% efficacy against variants "not considered Variants of Concern/Interest" All COVID-19 hospitalizations/death occurred in the placebo group Company to host investor conference call today at 8:30 am ET

GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary... More